Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:28 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
NCT06140407 · Vanderbilt-Ingram Cancer Center · PHASE2 · terminated · last registry update 2025-06-05 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low accrual and Merck discontinuing funding and drug supply” | – | Registry record, Vanderbilt-Ingram Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-21Phase 3 first posted: Hoffmann-La Roche, Divarasib + Pembrolizumab (NCT07541170)
- 2026-04-07Phase 3 first posted: Merck Sharp & Dohme LLC, Intismeran + Pembrolizumab coformulated with berahyaluronidase alfa (NCT07513376)
- 2026-02-25Phase 3 first posted: Merck Sharp & Dohme LLC, Calderasib + MK-3475A (NCT07431827)
- 2026-01-26Phase 3 first posted: Eikon Therapeutics, EIK1001 + Pembrolizumab (KEYTRUDA®) (NCT07365319)
- 2026-01-23Phase 3 first posted: Bristol-Myers Squibb, Pumitamig + Pembrolizumab (NCT07361510)
- 2025-09-29Phase 3 first posted: Boehringer Ingelheim, Zongertinib + Pembrolizumab (NCT07195695)
- 2025-09-24Phase 3 first posted: Merck Sharp & Dohme LLC, Calderasib + Pembrolizumab (+) Berahyaluronidase alfa (NCT07190248)
- 2025-09-09Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QL2107 + Keytruda® (NCT07162883)
- 2025-07-14Phase 3 first posted: Bristol-Myers Squibb, BMS-986504 + Pembrolizumab (NCT07063745)
- 2025-04-17Phase 3 first posted: ETOP IBCSG Partners Foundation, Cemiplimab (NCT06931717)
- 2025-03-27Phase 3 first posted: Daiichi Sankyo, Trastuzumab Deruxtecan + pembrolizumab (NCT06899126)
- 2025-03-24Phase 3 first posted: Eli Lilly and Company, Olomorasib + Pembrolizumab (NCT06890598)
- 2025-03-13Phase 3 first posted: Mirati Therapeutics Inc., Adagrasib + Pembrolizumab (NCT06875310)
- 2025-02-21Phase 3 first posted: Gustave Roussy, Cancer Campus, Grand Paris, SoC-based immunotherapy (+/- chemotherapy) (NCT06840782)
- 2025-01-27Phase 3 first posted: Hoffmann-La Roche, Divarasib + Pembrolizumab (NCT06793215)
- 2024-12-02Phase 3 first posted: BioNTech SE, Pumitamig + Pembrolizumab (NCT06712316)
- 2024-11-18Phase 3 first posted: AstraZeneca, Rilvegostomig + Pembrolizumab (NCT06692738)
- 2024-10-10Phase 3 first posted: Genmab, Acasunlimab + Pembrolizumab (NCT06635824)
- 2024-10-04Phase 3 first posted: AstraZeneca, Rilvegostomig + Pembrolizumab (NCT06627647)
- 2024-10-02Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Cisplatin (NCT06623422)
- 2024-08-20Phase 3 first posted: Bristol-Myers Squibb, Nivolumab + Relatlimab (NCT06561386)
- 2024-06-20Results posted on the registry: Eli Lilly and Company, Selpercatinib + Carboplatin (NCT04194944)
- 2024-06-11Phase 3 first posted: Bayer, Sevabertinib + Pembrolizumab (NCT06452277)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision